Objective::To assess the clinical effectiveness of an intravitreal injection of conbercept using two different strategies, the 3+PRN and 3+Q3M strategies, for the treatment of wet age-related macular degeneration (AMD).Methods::Prospective clinical study. Patients at Qilu Hospital, Shandong University who were confirmed to have exudative AMD from August 2018 to August 2019 were included. Exudative lesions of choroidal neovascularization (CNV) in the macular area were found in all 106 eyes of these patients. The international standard decimal visual acuity chart was used to measure best corrected visual acuity (BCVA). This was converted to the logarithm of the minimum angle of resolution (LogMAR) for the analysis. Optical coherence tomography (OCT) was used to measure central retinal thickness (CRT). For all eyes, an intravitreal injection of 0.5 mg of conbercept was administered with one of two strategies: 55 eyes received once monthly injections for the first 3 months, then 3+prore nata (3+PRN), and 51 eyes received once monthly injections for the first 3 months, followed by one injection every 3 months (3+Q3M). The patients were followed up for 12 months after the treatment. Routine examinations of BCVA, intraocular pressure (IOP), and OCT were conducted at 1 and 2 weeks after the operation, then these examinations were conducted every month. FFA examination was conducted every 3 months after the operation.The changes in BCVA, CRT and exudation of CNV lesions of the eyes were measured before and after treatment. Repeated measures analysis of variance was used to compare the groups and show the time effect, while the LSD t-test was used for comparisons among different time points within the same group. Results::The mean BCVA in both groups improved significantly at 1, 3, 6, 9 and 12 months after the operation, compared to the levels before treatment (3+PRN: t=7.202, 11.178, 9.914, 9.869, 10.587, respectively, P<0.001; 3+Q3M: t=5.548, 9.780, 9.358, 11.884, 11.622, respectively, P<0.001). In addition, the BCVA of the eyes was also significantly better in the 3+Q3M group than in the 3+PRN group at 9 and 12 months after the operation ( t=2.304, P=0.023; t=2.058, P=0.042). The mean CRT of the eyes was significantly lower at 1, 3, 6, 9 and 12 months after treatment, compared to the level before treatment (3+PRN: t=12.28, 17.041, 17.615, 15.739, 16.171, P<0.001; 3+Q3M: t=10.221, 15.598, 16.297, 16.984, 17.275, P<0.001). In addition, the CRT of the eyes was significantly lower in the 3+Q3M group than in the 3+PRN group at 9 and 12 months after the operation ( t=2.032, P=0.045; t=2.092, P=0.039). The FFA and ICGA examinations at the last follow-up showed that the exudation of CNV lesions in the macular area disappeared, reduced, or increased in 31(56%), 18(33%), and 6(11%) eyes in the 3+PRN group, and in 32(63%), 15(29%), and 4(8%) eyes in the 3+Q3M group, respectively. The Chi-square test shows the difference has no significance. There were no serious treatment-related ocular complications, such as retinal detachment, retinal tear, persistent intraocular pressure increase, or endophthalmitis, as well as serious systemic adverse responses found during the follow-up. Conclusions::Both strategies, namely the 3+PRN and 3+Q3M strategies, of intravitreal injection of conbercept are effective in treating wet AMD. However, the 3+Q3M strategy needs more injections but is more effective for improving visual acuity, reducing macular CRT thickness, and decreasing the exudation area of CNV, than the 3+PRN strategy.

患儿女,11个月,因发现右眼瞳仁区发白3个月于2010年10月10日就诊.入院查体:一般情况可,心肺检查无异常.眼部检查:双眼视力可追随灯光,右眼比左眼差.眼压:双眼指测正常.右眼角膜透明,前房深浅适中.瞳孔圆,直径约2mm,对光反射存在;晶状体呈灰白色不均匀性混浊,玻璃体及眼底均窥不清.左眼检查未见异常.眼球运动:遮盖左眼后,右眼不规则水平震颤.双眼B超示,右眼玻璃体腔有少量细小混浊,视盘表面见锥形膜状光带自视盘伸向玻璃体腔,眼球轴长19.8 mm.左眼玻璃体、眼球后壁及眶内未查及异常改变,眼球轴长约19.6 mm.考虑右眼为永存原始玻璃体增生症(PHPV).入院诊断:先天性白内障(右);PHPV(右).